Stephen K. Doberstein
2016
In 2016, Stephen K. Doberstein earned a total compensation of $1.7M as Senior Vice President and Chief Research and Development Officer at Nektar Therapeutics, a 48% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $266,805 |
|---|---|
| Option Awards | $504,526 |
| Salary | $508,200 |
| Stock Awards | $428,396 |
| Other | $12,806 |
| Total | $1,720,733 |
Doberstein received $508.2K in salary, accounting for 30% of the total pay in 2016.
Doberstein also received $266.8K in non-equity incentive plan, $504.5K in option awards, $428.4K in stock awards and $12.8K in other compensation.
Rankings
In 2016, Stephen K. Doberstein's compensation ranked 5,590th out of 14,075 executives tracked by ExecPay. In other words, Doberstein earned more than 60.3% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 5,590 out of 14,075 | 60th |
Division Manufacturing | 2,017 out of 5,488 | 63rd |
Major group Chemicals And Allied Products | 641 out of 1,900 | 66th |
Industry group Drugs | 482 out of 1,543 | 69th |
Industry Pharmaceutical Preparations | 382 out of 1,173 | 67th |
Source: SEC filing on April 30, 2018.
Doberstein's colleagues
We found four more compensation records of executives who worked with Stephen K. Doberstein at Nektar Therapeutics in 2016.
2016
Howard Robin
Nektar Therapeutics
Chief Executive Officer
2016
John Nicholson
Nektar Therapeutics
Chief Operating Officer
2016
Gil Labrucherie
Nektar Therapeutics
Chief Financial Officer
2016
Maninder Hora
Nektar Therapeutics